Prudential Financial
KLRS

Prudential Financial’s Kalaris Therapeutics KLRS Stock Holding History

Prudential Financial’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-639
Closed -$57.9K – 2725
2023
Q1 		$57.9K Sell
639
-152
-19% -$19.4K ﹤0.01% 2486
2022
Q4 		$93.4K Hold
791
– – ﹤0.01% 2455
2022
Q3 		$144K Buy
791
+52
+7% +$8.1K ﹤0.01% 2489
2022
Q2 		$66K Buy
+739
New +$77.5K ﹤0.01% 2553

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Prudential Financial's KLRS Position: Q2 2023 in Review

Prudential Financial sold out of Kalaris Therapeutics (KLRS) in Q2 2023, closing a stake of 639 shares — an estimated $57.9K sold.

Prudential Financial first reported a position in KLRS in Q2 2022 and held it in 4 quarters. The position peaked at $144K in Q3 2022. 94 funds tracked by Wall St. Rank hold KLRS as of Q2 2023.

  • Prudential Financial reported no remaining Kalaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Prudential Financial sold 639 Kalaris Therapeutics shares in Q2 2023, an estimated $57.9K.
  • Prudential Financial first reported a position in Kalaris Therapeutics in Q2 2022 and held it in 4 quarters.
  • Prudential Financial's Kalaris Therapeutics position peaked at $144K in Q3 2022.
  • 94 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2023.

Based on Prudential Financial's 13F filing for Q2 2023, filed 11 Aug 2023.